Mesoporous Platinum Nanotherapeutics For Combined Chemo-Photothermal Cancer Treatment

Wencong Zhao,Zhenhua Li,Hua Yang,Cui Ren,Fangfang Lv,Shutao Gao,Huanyun Ma,Yi Jin,Kun Ge,Dandan Liu,Jinchao Zhang,Huifang Liu
DOI: https://doi.org/10.1021/acsabm.9b00250
2019-01-01
ACS Applied Bio Materials
Abstract:Recently, nanoparticles that possess combined use in synergistic therapy, real-time imaging, and spatiotemporally controlled therapies have attracted enormous attention. Herein, we fabricated Doxorubicin (DOX)-loaded and beta-cyclodextrin (beta-CD)-capped mesoporous platinum nanoparticles (MPNPs) (DOX/MPNPs-AD-CD) for combined chemo-photothermal cancer therapy. DOX/MPNPs-AD-CD with high photothermal effect and loading rate could release the anticancer drugs stimulated by acidic tumor microenvironment or near-infrared light. Moreover, acid-degradable MPNPs would release cytotoxic Pt2+, which would enhance the efficiency of chemotherapy. In addition, the inherent photoacoustic and photothermal imaging can effectively guide chemo-photothermal therapy to achieve the desired treatment. Taken together, DOX/MPNPs-AD-CD possess the abilities of combined chemo-photothermal therapy and dual-imaging properties. The studies demonstrated that DOX/MPNPs-AD-CD could effectively inhibit tumor cell growth in vivo and in vitro. Thus, this treatment platform is expected to be one of interest for the clinical treatment of cancers.
What problem does this paper attempt to address?